腮腺区广泛型复发性多形性腺瘤的面神经处理及术后放疗经验：附10例报告

doi:10.19439/j.sjos.2021.06.021

上海口腔医学 ›› 2021, Vol. 30 ›› Issue (6): 667-672.doi: 10.19439/j.sjos.2021.06.021

• 临床总结 • 上一篇

腮腺区广泛型复发性多形性腺瘤的面神经处理及术后放疗经验：附10例报告

徐万林¹, 朱云¹, 卢浩¹, 丁继平², 姚原², 刘胜文^1,*, 张陈平¹, 杨雯君^1,*

1.上海交通大学医学院附属第九人民医院口腔颌面-头颈肿瘤科,上海交通大学口腔医学院,国家口腔医学中心,国家口腔疾病临床医学研究中心,上海市口腔医学重点实验室,上海 200011;
2.上海交通大学医学院附属第九人民医院放疗科,上海 200011

收稿日期:2020-05-28 修回日期:2020-08-22 发布日期:2022-03-09
通讯作者: 杨雯君,E-mail：ywjdoctor@163.com;刘胜文,E-mail：wubenzhimu@163.com。^*共同通信作者
作者简介:徐万林（1989-）,男,博士,住院医师,E-mail：xwl570127181@163.com
基金资助:
上海市科委青年科技杨帆计划（21YF1423500）; 上海交通大学医学院附属第九人民医院生物样本库项目（YBKB201920）

Experience of facial nerve management and postoperative radiotherapy in general recurrent pleomorphic adenoma of parotid gland: report of 10 consecutive cases

XU Wan-lin¹, ZHU Yun¹, LU Hao¹, DING Ji-ping², YAO Yuan², LIU Sheng-wen¹, ZHANG Chen-ping¹, YANG Wen-jun¹

1. Department of Oromaxillofacial Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine; College of Stomatology, Shanghai Jiao Tong University; National Center for Stomatology; National Clinical Research Center for Oral Diseases; Shanghai Key Laboratory of Stomatology. Shanghai 200011;
2. Department of Radiation Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine. Shanghai 200011, China

Received:2020-05-28 Revised:2020-08-22 Published:2022-03-09

摘要/Abstract

摘要： 目的: 总结腮腺区广泛型复发性多形性腺瘤的面神经处理及术后放疗的相关经验。方法: 对收集的10例腮腺区广泛型复发性多形性腺瘤患者的临床特征进行分析,重点分析术中面神经处理方法及术后放疗的作用。结果: 10例患者中,男6例,女4例;年龄23~51岁,平均38岁（中位年龄37岁）。10例患者均具有多次术后复发特点,其中6例首次术式为局麻下肿瘤结节摘除术。所有患者均接受手术治疗,术式为腮腺全叶切除术结合术中具体情况处理面神经（完整保留5例、端-端吻合2例、耳大神经桥接2例、咬肌神经转位修复1例）。所有患者均接受术后放疗,放疗剂量为55~62 Gy/25~30 Fx,随访至今未见肿瘤复发。结论: 腮腺区广泛型复发性多形性腺瘤有多次复发、侵袭性强等特点,手术应注意在彻底切除肿瘤的同时,尽可能保护面神经。无法保留完整性时,则切除受累段、同期修复重建,辅助放疗可能对提高局部控制率有一定帮助。

关键词: 复发性多形性腺瘤, 广泛复发, 腮腺肿瘤, 面神经, 放疗

Abstract: PURPOSE: To preliminarily summarize the experience of facial nerve management and postoperative radiotherapy in general recurrent pleomorphic adenoma of parotid gland. METHODS: The clinical features of general recurrent pleomorphic adenoma of parotid gland were reviewed and analyzed, with emphasis on facial nerve management and postoperative radiotherapy. RESULTS: A total of 10 cases (6 males and 4 females) of general recurrent pleomorphic adenoma of parotid gland were collected. The age ranged from 23-51 years (mean: 38, median: 37). All patients suffered from multiple-recurred lesions. The initial management of 6 patients were removal of the tumor nodule under local anesthesia. Total parotidectomy plus facial nerve management based on specific situation (complete preservation in 5 cases, side-to-side anastomosis in 2 cases, great auricular nerve abridgement in 2 cases and masseter nerve transposition in 1 case) were performed. All the ten cases received adjuvant radiotherapy (dose: 55-62 Gy/25-30 Fx), and no tumor recurrence happened to date. CONCLUSIONS: The general recurrent pleomorphic adenoma of parotid gland may relapse repeatedly and invade widely. Surgery should be performed to remove the tumor thoroughly and protect the facial nerve as much as possible, and adjuvant radiotherapy may be beneficial to improve local control rate.

Key words: Recurrent pleomorphic adenoma, General recurrence, Parotid gland tumor, Facial nerve, Radiotherapy

中图分类号:

R739.8

徐万林, 朱云, 卢浩, 丁继平, 姚原, 刘胜文, 张陈平, 杨雯君. 腮腺区广泛型复发性多形性腺瘤的面神经处理及术后放疗经验：附10例报告[J]. 上海口腔医学, 2021, 30(6): 667-672.

XU Wan-lin, ZHU Yun, LU Hao, DING Ji-ping, YAO Yuan, LIU Sheng-wen, ZHANG Chen-ping, YANG Wen-jun. Experience of facial nerve management and postoperative radiotherapy in general recurrent pleomorphic adenoma of parotid gland: report of 10 consecutive cases[J]. Shanghai Journal of Stomatology, 2021, 30(6): 667-672.

参考文献

[1] Tian Z, Li L, Wang L, et al.Salivary gland neoplasms in oral and maxillofacial regions: a 23-year retrospective study of 6982 cases in an eastern Chinese population[J]. Int J Oral Maxillofac Surg, 2010, 39(3): 235-242.
[2] Gao M, Hao Y, Huang MX, et al.Salivary gland tumours in a northern Chinese population: a 50-year retrospective study of 7190 cases[J]. Int J Oral Maxillofac Surg, 2017, 46(3): 343-349.
[3] 黄立勋, 翦新春. 腮腺复发性多形性腺瘤的临床分析—附22例报告[J]. 口腔医学研究, 2003, 19(1): 68-70.
[4] Bonavolonta P, Dell'Aversana Orabona G, Maglitto F, et al. Postoperative complications after removal of pleomorphic adenoma from the parotid gland: a long-term follow up of 297 patients from 2002 to 2016 and a review of publications[J]. Br J Oral Maxillofac Surg, 2019, 57(10): 998-1002.
[5] Barzan L, Pin M.Extra-capsular dissection in benign parotid tumors[J]. Oral Oncol, 2012, 48(10): 977-979.
[6] Werner RL, Castle JT.Recurrent pleomorphic adenoma[J]. Head Neck Pathol, 2014, 8(3): 303-306.
[7] Witt RL, Eisele DW, Morton RP, et al.Etiology and management of recurrent parotid pleomorphic adenoma[J]. Laryngoscope, 2015, 125(4): 888-893.
[8] 黄敏娴, 马大权, 俞光岩, 等. 复发性涎腺多形性腺瘤的临床与病理分析[J]. 现代口腔医学杂志, 2008, 22(1): 1-4.
[9] Kanatas A, Ho MWS, Mucke T.Current thinking about the management of recurrent pleomorphic adenoma of the parotid: a structured review[J]. Br J Oral Maxillofac Surg, 2018, 56(4): 243-248.
[10] 刘杰, 黄建涛, 姜蕾, 等. 腮腺复发性多形性腺瘤二次复发的多因素分析[J]. 中国口腔颌面外科杂志, 2010, 8(1): 79-84.
[11] 徐万林, 朱云, 卢浩, 等. 15例下颌下腺复发性多形性腺瘤临床病理分析[J]. 中国口腔颌面外科杂志, 2019, 17(5): 465-468.
[12] Shen S, Yang W, Wang Z, et al.Tumor-initiating cells are enriched in CD44(hi) population in murine salivary gland tumor[J]. PLoS One, 2011, 6(8): e23282.
[13] Shen S, Lu H, Liu L, et al.The role of CD44 in tumor-initiating cells of salivary gland pleomorphic adenoma: more than a surface biomarker[J]. Oral Dis, 2020, 26(3): 547-557.
[14] Wittekindt C, Streubel K, Arnold G, et al.Recurrent pleomorphic adenoma of the parotid gland: analysis of 108 consecutive patients[J]. Head Neck, 2007, 29(9): 822-828.
[15] 邓刚, 李晓光, 何悦, 等. 复发性腮腺多形性腺瘤的手术治疗及并发症预防[J]. 中国口腔颌面外科杂志, 2017, 15(3): 227-230.
[16] Zhu Y, Xu W, Zhang C, et al.Facial nerve preservation during giant mandibular tumor surgery[J]. J Craniofac Surg, 2017,28(2): e115-e117.
[17] Makeieff M, Venail F, Cartier C, et al.Continuous facial nerve monitoring during pleomorphic adenoma recurrence surgery[J]. Laryngoscope, 2005, 115(7): 1310-1314.
[18] Mc Loughlin L, Gillanders SL, Smith S, et al.The role of adjuvant radiotherapy in management of recurrent pleomorphic adenoma of the parotid gland: a systematic review[J]. Eur Arch Otorhinolaryngol, 2019, 276(2): 283-295.
[19] Chen AM, Garcia J, Bucci MK, et al.Recurrent pleomorphic adenoma of the parotid gland: long-term outcome of patients treated with radiation therapy[J]. Int J Radiat Oncol Biol Phys, 2006, 66(4): 1031-1035.
[20] Abu-Ghanem Y, Mizrachi A, Popovtzer A, et al.Recurrent pleomorphic adenoma of the parotid gland: Institutional experience and review of the literature[J]. J Surg Oncol, 2016, 114(6): 714-718.
[21] Leonetti JP, Marzo SJ, Petruzzelli GJ, et al.Recurrent pleomorphic adenoma of the parotid gland[J]. Otolaryngol Head Neck Surg, 2005, 133(3): 319-322.
[22] Zhu Y, Zhou S, Xu W, et al.Effects of postoperative radiotherapy on vascularized nerve graft for facial nerve repair in a rabbit model[J]. J Oral Maxillofac Surg, 2019, 77(11): 2339-2346.

腮腺区广泛型复发性多形性腺瘤的面神经处理及术后放疗经验：附10例报告

Experience of facial nerve management and postoperative radiotherapy in general recurrent pleomorphic adenoma of parotid gland: report of 10 consecutive cases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 5

编辑推荐

Metrics

本文评价

[1]	董振耀, 杨世荣, 姚毅章. 爱维治对放疗所致急性口腔黏膜炎的疗效观察[J]. 上海口腔医学, 2021, 30(1): 89-92.
[2]	齐鑫, 谢敬生, 王梓欣. 腮腺保留式调强放疗对唾液组成、流量及口干的影响[J]. 上海口腔医学, 2020, 29(4): 396-399.
[3]	高明华, 尹雪莱, 胡永杰, 盛美春, 王忠华, 郑重阳, 张新宇, 吴海威. 52例腮腺区神经鞘瘤临床治疗及预后分析[J]. 上海口腔医学, 2018, 27(4): 411-414.
[4]	黄育萌, 王颖, 李勇, 刘平, 柳先锋, 赵洪伟. 不同放疗剂量对人唾液腺腺样囊性癌细胞生物学行为的影响[J]. 上海口腔医学, 2016, 25(4): 403-408.
[5]	魏海刚,李蜀光,陈玉婷,蔡超雄,许彪. 神经损伤诱导面神经运动神经元死亡及caspase相关蛋白的表达[J]. 上海口腔医学, 2015, 24(1): 23-29.